Yes, individuals with a pathogenic MYH11 gene variant absolutely require thoracic aortic aneurysm screening.
Persons with pathogenic or likely pathogenic MYH11 variants should undergo baseline imaging of the thoracic aorta with transthoracic echocardiography (TTE), or with CT/MRI if the ascending aorta is not adequately visualized by TTE, followed by annual surveillance imaging if stable 1.
Screening Protocol
The 2022 ACC/AHA guidelines provide clear direction for MYH11 variant carriers 1:
- Baseline imaging: TTE is the initial modality, with CT or MRI reserved for inadequate TTE visualization of the ascending aorta
- Surveillance frequency: Annual imaging when stable
- Extended surveillance: The aortic arch and descending aorta may also dilate and require monitoring
- Less frequent imaging: May be considered only when the aorta is completely normal, factoring in the specific variant, patient age, and family history
Medical Management
Beta-blocker therapy is recommended to reduce hemodynamic stress on the aortic wall 1.
Disease-Specific Characteristics of MYH11
MYH11 pathogenic variants confer highly penetrant risk for thoracic aortic disease inherited in an autosomal dominant pattern 1, 2. Key clinical features include:
- Primary presentation: Type A or B aortic dissection
- Aneurysm location: Predominantly involves the aortic root and ascending aorta
- Critical threshold: Type A dissection may occur at aortic diameters <5.0 cm 1
- Associated conditions: May include patent ductus arteriosus and peripheral arterial disease
- Additional vascular risks: Screening for coronary and cerebrovascular disease may be warranted in specific variants
Surgical Timing Considerations
The decision for prophylactic aortic repair is based on:
- Absolute aortic diameter
- Patient age
- Family history of dissection
- Presence of additional risk factors
The lower dissection threshold (<5.0 cm) in MYH11 carriers makes surveillance particularly critical, as dissection can occur at smaller diameters than in the general population 1.
Important Caveats
Incomplete Penetrance
Research demonstrates that MYH11 variants show incomplete segregation with disease in some families 3. This means:
- Not all variant carriers will develop aortic disease
- Non-carriers in affected families may still require surveillance
- An oligogenic model may explain variable onset and reduced penetrance
However, this incomplete penetrance does not negate the need for screening—it actually reinforces it, as we cannot predict which carriers will develop life-threatening aortic disease 3.
Variant Interpretation Challenges
Recent evidence highlights that MYH11 copy number variations are frequently misannotated in clinical genetic testing 4. Deletions may be incorrectly categorized as pathogenic, while duplications may be incorrectly labeled benign. This underscores the importance of expert interpretation of genetic results.
Clinical Bottom Line
Given that MYH11 variants are classified among the 11 genes with definitive evidence for highly penetrant heritable thoracic aortic disease 2, and that dissection can occur at relatively small aortic diameters with potentially fatal consequences, screening is not optional—it is a guideline-directed, life-saving intervention 1.